Rotate Device
References
  1. Data on file, HOYA Medical Singapore Pte. Ltd, 2018.
  2. Matsushima H, et al. Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. J Cataract Refract Surg. 2006;32:1035-1040.

Our Nanex™ IOLs

Proven hydrophobic acrylic lens material:

over 10 million units implanted worldwide, over 20 years1

Significant PCO reduction:

achieved through HOYA’s proprietary active oxygen processing treatment to the posterior surface of the Nanex™ IOL2

References

Third-party trademarks used herein are the property of their respective owners.

  1. Balendiran V, et al. Uveal and capsular biocompatibility of a new hydrophobic acrylic microincision intraocular lens. J Cataract Refract Surg. 2020; 46:459-464.
  2. Data on file, HOYA Medical Singapore Pte. Ltd, 2019.

Demonstrated PCO reduction

Nanex™ multiSert+™ showed a consistent trend towards stronger PCO inhibition versus AcrySof® IQ across all three scores1,2

In a GLP-study evaluating the PCO of Nanex™ multiSert+™ (NC1-SP) and AcrySof® IQ (SN60WF) in rabbits, while not statistically significant, Nanex™ multiSert+™ showed a trend towards less PCO in comparison with AcrySof® IQ, in the 4-week postoperative study.

References
  1. Matsushima H, et al. Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. J Cataract Refract Surg. 2006; 32:1035-1040. 
  2. Data on file, HOYA Medical Singapore Pte. Ltd, 2019.

What features of an IOL limit PCO?

Active oxygen processing treatment to reduce PCO

Improves adhesion between the posterior surface of the IOL and the capsule by creating functional groups on the IOL surface1

Square posterior
optic edge

Designed to minimize PCO2

Scroll

scroll scroll